|
|
Vaccine Detail
|
Hexapeptide melanoma vaccine |
| Vaccine Information |
- Vaccine Name: Hexapeptide melanoma vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007494
- Type: multipeptide
- Status: Clinical trial
- Antigen: gp100, tyrosinase, MART1, MAGEA
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Human Response
- Vaccine Immune Response Type: VO_0003057
- Immune Response: Proliferation assays revealed induction of T-cell responses to the melanoma helper peptides in 81% of patients (Slingluff et al., 2008).
|
| References |
Slingluff et al., 2008: Slingluff CL Jr, Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, Chianese-Bullock KA, Neese PY, Deacon DH, Nail C, Merrill P, Fink R, Patterson JW, Rehm PK. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008; 26(30); 4973-4980. [PubMed: 18809608].
|
|
